HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2018 Sep 11

PMID 30199098

Citations 15

Authors

Craig W Hendrix

Affiliations

Soon will be listed here.

Abstract

The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis of human immunodeficiency virus (HIV) infection in 2012 on the basis of two randomized controlled trials (RCTs), one in men who have sex with men (MSM) and another in HIV serodiscordant heterosexual couples. Subsequently, even greater efficacy has been demonstrated in MSM with rapid population-level incidence reductions in some locations. In contrast, studies of antiretroviral pre-exposure prophylaxis (PrEP) in heterosexual women showed only modest or no efficacy, largely attributed to low adherence. The mixed results of antiretroviral-based PrEP bear witness to unique drug development challenges at this complicated intersection of sexual behavior, public health, and drug development. Multiple innovative methods and formulation strategies followed to address unmet medical needs of persons struggling with daily oral PrEP adherence or preference for nonsystemic PrEP options. Clinical pharmacology plays essential roles throughout this PrEP development process, especially in early product development and through pharmacologically informed enhancement and interpretation of clinical trials.

Citing Articles

Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug.

Akhavein N, Baum M, Gunawardana M, Moss J, Calvez S, Remedios-Chan M Sci Rep. 2024; 14(1):11573.

PMID: 38773172 PMC: 11109207. DOI: 10.1038/s41598-024-58583-w.

Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.

Zhang L, Iannuzzi S, Chaturvedula A, Irungu E, Haberer J, Hendrix C Nat Med. 2023; 29(11):2753-2762.

PMID: 37957377 PMC: 10667095. DOI: 10.1038/s41591-023-02615-x.

Approved HIV reverse transcriptase inhibitors in the past decade.

Li G, Wang Y, De Clercq E Acta Pharm Sin B. 2022; 12(4):1567-1590.

PMID: 35847492 PMC: 9279714. DOI: 10.1016/j.apsb.2021.11.009.

Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.

Gunawardana M, Remedios-Chan M, Sanchez D, Webster S, Castonguay A, Webster P Sci Rep. 2022; 12(1):8224.

PMID: 35581262 PMC: 9114338. DOI: 10.1038/s41598-022-11020-2.

Mapping Interests in Event-Driven and Long-Acting Pre-exposure Prophylaxis Formulations onto the HIV Risk Environment of Street-Based Female Sex Workers: A Latent Class Analysis.

Rosen J, Park J, Schneider K, White R, Beckham S, Glick J AIDS Behav. 2022; 26(6):1992-2002.

PMID: 35362908 PMC: 9050919. DOI: 10.1007/s10461-022-03613-9.

References

Taneva E, Sinclair S, Mesquita P, Weinrick B, Cameron S, Cheshenko N . Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. JCI Insight. 2018; 3(13). PMC: 6124523. DOI: 10.1172/jci.insight.99545. View

Leyva F, Fuchs E, Bakshi R, Carballo-Dieguez A, Ventuneac A, Yue C . Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. AIDS Res Hum Retroviruses. 2015; 31(11):1089-97. PMC: 4651043. DOI: 10.1089/AID.2015.0086. View

Herold B, Chen B, Salata R, Marzinke M, Kelly C, Dezzutti C . Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Clin Infect Dis. 2015; 62(3):375-382. PMC: 4706638. DOI: 10.1093/cid/civ913. View

Ruane P, DeJesus E, Berger D, Markowitz M, Bredeek U, Callebaut C . Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013; 63(4):449-55. DOI: 10.1097/QAI.0b013e3182965d45. View

DiFrancesco R, Tooley K, Rosenkranz S, Siminski S, Taylor C, Pande P . Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin Pharmacol Ther. 2013; 93(6):479-82. PMC: 3970711. DOI: 10.1038/clpt.2013.62. View

Hendrix C . Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013; 155(3):515-8. DOI: 10.1016/j.cell.2013.09.030. View

Abdool Karim S, Richardson B, Ramjee G, Hoffman I, Chirenje Z, Taha T . Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25(7):957-66. PMC: 3083640. DOI: 10.1097/QAD.0b013e32834541d9. View

Denton P, Othieno F, Martinez-Torres F, Zou W, Krisko J, Fleming E . One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol. 2011; 85(15):7582-93. PMC: 3147928. DOI: 10.1128/JVI.00537-11. View

Cottrell M, Yang K, Prince H, Sykes C, White N, Malone S . A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. 2016; 214(1):55-64. PMC: 4907409. DOI: 10.1093/infdis/jiw077. View

10.

McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M . PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329-37. PMC: 2956883. DOI: 10.1016/S0140-6736(10)61086-0. View

11.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

12.

Garcia-Lerma J, Aung W, Cong M, Zheng Q, Youngpairoj A, Mitchell J . Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol. 2011; 85(13):6610-7. PMC: 3126530. DOI: 10.1128/JVI.00311-11. View

13.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

14.

Chen J, Flexner C, Liberman R, Skipper P, Louissaint N, Tannenbaum S . Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr. 2012; 61(5):593-9. PMC: 3509498. DOI: 10.1097/QAI.0b013e3182717c98. View

15.

Hendrix C, Andrade A, Bumpus N, Kashuba A, Marzinke M, Moore A . Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2015; 32(1):32-43. PMC: 4692123. DOI: 10.1089/AID.2015.0182. View

16.

Zablotska I, Selvey C, Guy R, Price K, Holden J, Schmidt H . Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. BMC Public Health. 2018; 18(1):210. PMC: 5797394. DOI: 10.1186/s12889-017-5018-9. View

17.

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

18.

Patterson K, Prince H, Kraft E, Jenkins A, Shaheen N, Rooney J . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011; 3(112):112re4. PMC: 3483088. DOI: 10.1126/scitranslmed.3003174. View

19.

Chen X, Castillo-Mancilla J, Seifert S, McAllister K, Zheng J, Bushman L . Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother. 2016; 60(9):5387-92. PMC: 4997838. DOI: 10.1128/AAC.01019-16. View

20.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N . Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008; 5(8):e157. PMC: 2494562. DOI: 10.1371/journal.pmed.0050157. View